117 related articles for article (PubMed ID: 9709738)
1. Brimonidine and pupillary diameter.
Mastropasqua L; Carpineto P; Ciancaglini M
Ophthalmology; 1998 Aug; 105(8):1352-3. PubMed ID: 9709738
[No Abstract] [Full Text] [Related]
2. [Clinical efficacy of 0.2% brimonidine in patients with open-angle glaucoma or ocular hypertension].
Shi JM; Jiang YQ
Hunan Yi Ke Da Xue Xue Bao; 2002 Jun; 27(3):263-6. PubMed ID: 12575311
[TBL] [Abstract][Full Text] [Related]
3. Brimonidine tartrate: a one-month dose response study.
Derick RJ; Robin AL; Walters TR; Barnebey HS; Choplin N; Schuman J; Kelley EP; Chen K; Stoecker JF
Ophthalmology; 1997 Jan; 104(1):131-6. PubMed ID: 9022117
[TBL] [Abstract][Full Text] [Related]
4. [The ocular hypotensive effect and safety of 0.2% brimonidine].
Yu M; Li Y; Ge J
Yan Ke Xue Bao; 2001 Dec; 17(4):235-8. PubMed ID: 12567513
[TBL] [Abstract][Full Text] [Related]
5. Development and use of brimonidine in treating acute and chronic elevations of intraocular pressure: a review of safety, efficacy, dose response, and dosing studies.
Walters TR
Surv Ophthalmol; 1996 Nov; 41 Suppl 1():S19-26. PubMed ID: 8970246
[TBL] [Abstract][Full Text] [Related]
6. Brimonidine: a new alpha2-adrenoreceptor agonist for glaucoma treatment.
Greenfield DS; Liebmann JM; Ritch R
J Glaucoma; 1997 Aug; 6(4):250-8. PubMed ID: 9264305
[TBL] [Abstract][Full Text] [Related]
7. Comparing brimonidine 0.2% to apraclonidine 1.0% in the prevention of intraocular pressure elevation and their pupillary effects following laser peripheral iridotomy.
Yuen NS; Cheung P; Hui SP
Jpn J Ophthalmol; 2005; 49(2):89-92. PubMed ID: 15838723
[TBL] [Abstract][Full Text] [Related]
8. A comparison of the safety and efficacy of twice daily brimonidine 0.2% versus betaxolol 0.25% in subjects with elevated intraocular pressure. The Brimonidine Study Group III.
Serle JB
Surv Ophthalmol; 1996 Nov; 41 Suppl 1():S39-47. PubMed ID: 8970248
[TBL] [Abstract][Full Text] [Related]
9. The safety and intraocular pressure-lowering efficacy of brimonidine tartrate 0.15% preserved with polyquaternium-1.
Whitson JT; Ochsner KI; Moster MR; Sullivan EK; Andrew RM; Silver LH; Wells DT; James JE; Bosworth CF; Dickerson JE; Landry TA; Bergamini MV;
Ophthalmology; 2006 Aug; 113(8):1333-9. PubMed ID: 16877072
[TBL] [Abstract][Full Text] [Related]
10. Comparison of the ocular hypotensive efficacy of adjunctive brimonidine 0.15% or brinzolamide 1% in combination with travoprost 0.004%.
Feldman RM; Tanna AP; Gross RL; Chuang AZ; Baker L; Reynolds A; Prager TC;
Ophthalmology; 2007 Jul; 114(7):1248-54. PubMed ID: 17509688
[TBL] [Abstract][Full Text] [Related]
11. Comparison between latanoprost and brimonidine efficacy and safety in Indian eyes.
Thomas R; Parikh R; Muliyil J; George R; Paul P; Abraham LM
Indian J Ophthalmol; 2003 Jun; 51(2):123-8. PubMed ID: 12831141
[TBL] [Abstract][Full Text] [Related]
12. The effectiveness and safety of brimonidine as mono-, combination, or replacement therapy for patients with primary open-angle glaucoma or ocular hypertension: a post hoc analysis of an open-label community trial. Glaucoma Trial Study Group.
Lee DA; Gornbein J; Abrams C
J Ocul Pharmacol Ther; 2000 Feb; 16(1):3-18. PubMed ID: 10673126
[TBL] [Abstract][Full Text] [Related]
13. An eight-week, multicentric, randomized, interventional, open-label, phase 4, parallel comparison of the efficacy and tolerability of the fixed combination of timolol maleate 0.5%/brimonidine tartrate 0.2% versus fixed combination of timolol maleate 0.5%/dorzolamide 2% in patients with elevated intraocular pressure.
Hatanaka M; Grigera DE; Barbosa WL; Jordao M; Susanna R
J Glaucoma; 2008 Dec; 17(8):674-9. PubMed ID: 19092465
[TBL] [Abstract][Full Text] [Related]
14. Systemic beta-blocker therapy and brimonidine and timolol.
Coulibaly R
Ophthalmology; 2001 Aug; 108(8):1368. PubMed ID: 11470677
[No Abstract] [Full Text] [Related]
15. Effects of brimonidine 0.2% on blue-yellow perimetry of glaucomatous patients.
Mastropasqua L; Ciancaglini M; Carpineto P; Zuppardi E; Falconio G; Gallenga PE
Acta Ophthalmol Scand Suppl; 1998; (227):36. PubMed ID: 9972338
[TBL] [Abstract][Full Text] [Related]
16. Dorzolamide/timolol combination versus concomitant administration of brimonidine and timolol: six-month comparison of efficacy and tolerability.
Sall KN; Greff LJ; Johnson-Pratt LR; DeLucca PT; Polis AB; Kolodny AH; Fletcher CA; Cassel DA; Boyle DR; Skobieranda F
Ophthalmology; 2003 Mar; 110(3):615-24. PubMed ID: 12623832
[TBL] [Abstract][Full Text] [Related]
17. Adherence with brimonidine in patients with glaucoma aware and not aware of electronic monitoring.
Hermann MM; Papaconstantinou D; Muether PS; Georgopoulos G; Diestelhorst M
Acta Ophthalmol; 2011 Jun; 89(4):e300-5. PubMed ID: 21106046
[TBL] [Abstract][Full Text] [Related]
18. Twenty-four-hour efficacy of the brimonidine/timolol fixed combination versus therapy with the unfixed components.
Konstas AG; Katsimpris IE; Kaltsos K; Georgiadou I; Kordelou A; Nelson LA; Stewart WC
Eye (Lond); 2008 Nov; 22(11):1391-7. PubMed ID: 17571086
[TBL] [Abstract][Full Text] [Related]
19. Selectivity of site of action and systemic effects of topical alpha agonists.
Robin AL; Burnstein Y
Curr Opin Ophthalmol; 1998 Apr; 9(2):30-3. PubMed ID: 10180510
[TBL] [Abstract][Full Text] [Related]
20. Brimonidine 0.15% versus apraclonidine 0.5% for prevention of intraocular pressure elevation after anterior segment laser surgery.
Chen TC
J Cataract Refract Surg; 2005 Sep; 31(9):1707-12. PubMed ID: 16246772
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
